Flecainide (monotherapy)
Pre-clinicalRecruiting 0 watching 0 views this weekπ€ Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Premature Ventricular Beats
Conditions
Premature Ventricular Beats, Premature Ventricular Complexes, Premature Ventricular Contraction (PVC), Arrhythmia Ventricular, Ventricular Dysfunction, Left, Ventricular Dysfunction, Cardiomyopathies, Secondary, Cardiomyopathies
Trial Timeline
Apr 26, 2024 β Dec 1, 2027
NCT ID
NCT06949748About Flecainide (monotherapy)
Flecainide (monotherapy) is a pre-clinical stage product being developed by Brain Biotech for Premature Ventricular Beats. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06949748. Target conditions include Premature Ventricular Beats, Premature Ventricular Complexes, Premature Ventricular Contraction (PVC).
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06949748 | Pre-clinical | Recruiting |
Competing Products
8 competing products in Premature Ventricular Beats
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| dapoxetine | Yuhan | Phase 1/2 | 41 |
| PSD502, contains a mixture of lidocaine and prilocaine + Placebo | Shionogi | Phase 2/3 | 65 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 85 |
| SHR7280οΌGanirelix Acetate Injection simulant + SHR7280 simulantοΌ Ganirelix Acetate Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ranolazine | Gilead Sciences | Phase 2 | 51 |
| IX-01 + Placebo | ICON plc. | Phase 2 | 49 |
| Tramadol Hydrochloride & Placebo | Bausch Health | Phase 3 | 72 |
| Tramadol Hydrochloride + Placebo | Bausch Health | Phase 3 | 72 |